A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia

PI3Kδ (idelalisib) and BTK (ibrutinib) inhibitors have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) interfering with the cross-talk between CLL cells and the lymph node microenviroment, yet their mechanism of action remains to be fully elucidated. Here, we develop...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Primo, Daniel, Scarfò, Lydia, Xochelli, Aliki, Mattsson, Mattias, Ranghetti, Pamela, Espinosa, Ana Belén, Robles, Alicia, Gorrochategui, Julian, Martínez-López, Joaquín, de la Serna, Javier, González, Marcos, Gil, Alberto Chaparro, Anguita, Eduardo, Iraheta, Sandra, Munugalavadla, Veerendra, Quéva, Christophe, Tannheimer, Stacey, Rosenquist, Richard, Stamatopoulos, Kostas, Ballesteros, Joan, Ghia, Paolo
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2018
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995261/
https://ncbi.nlm.nih.gov/pubmed/29899839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25419
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन